Acellular Dermal Matrix-assisted Implant-based Breast Reconstruction: Surgical and Patient-reported Outcomes From the Mastectomy Reconstruction Outcomes Consortium Study - PubMed
4 hours ago
- #acellular dermal matrix
- #breast reconstruction
- #patient-reported outcomes
- The study evaluated SurgiMend ADM in immediate 2-stage subpectoral implant-based breast reconstruction compared to no ADM using data from the Mastectomy Reconstruction Outcomes Consortium.
- Composite clinical success, defined as a BREAST-Q score decline of ≤4 points at 1 year and no major complications within 2 years, was significantly higher with SurgiMend (32.4% vs. 21.1%; difference 11.2%, P=0.02).
- Major complications were lower in the SurgiMend group (33.7% vs. 46.7%) after propensity-adjusted analysis, and patient-reported BREAST-Q scores were higher at 1 year (44.5% vs. 39.1%).
- The study concludes that SurgiMend is associated with fewer complications and better patient-reported outcomes, supporting its safety and effectiveness in postmastectomy reconstruction.
- Disclosures note funding and employment ties to Integra LifeSciences, with SurgiMend having FDA 'approvable pending good manufacturing practice' status but not yet marketed in the U.S.